• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates
Home » Sunshine Heart’s David Rosa: “Patients don’t like being tethered to a device”

Sunshine Heart’s David Rosa: “Patients don’t like being tethered to a device”

April 30, 2012 By Arezu Sarvestani

Click here to listen to the podcast

Sunshine Heart CEO David Rosa

"In the U.S., for Class III heart failure there are about 1.5 million patients," Sunshine Heart CEO David Rosa told MassDevice.com in an exclusive podcast interview. "That’s about 7 times the Class IV market, which is traditionally where LVADs participate."

And that’s the market Sunshine Heart is targeting with its flagship C-Pulse cardiac assist system, an outside-the-bloodstream heart pump designed for patients with Class III or early Class IV heart failure.

Sign up to get our free newsletters delivered right to your inbox

The device reduces the amount of pumping burden on a patient’s heart, providing some relief for common symptoms of heart failure, which include shortness of breath and reduced mobility.


MassDevice.com podcast

Click to play

Unlike traditional left ventricular assist devices, C-Pulse sits outside the bloodstream. Because the device has no contact with the blood, patients can reduce or in some cases eliminate their reliance on blood-thinning drugs.

It also means that patients can disconnect the device for short durations in order to shower, drive a car or engage in other activities that heart failure device patients are generally cautioned against.

In the recently released results of a feasibility trial, patients with Sunshine Heart’s C-Pulse system had no reported strokes or other neurological events. More than 85% of patients reported an improved quality of life, and 2 patients improved enough that they were able to disconnect their devices for prolonged periods of time without their symptoms reappearing.

"One patient in particular has been disconnected coming up on a year and a half now without any additional recurrent heart failure symptoms," Rosa told us. "That was unexpected, but quite exciting for us."

In the last year, Sunshine Heart completed a feasibility trial for its fully implantable C-Pulse system, completed 5 research & development programs and began listing SSH shares on the NASDAQ stock exchange.

Listen to MassDevice.com’s podcast interview with Sunshine Heart CEO David Rosa

The company has its sights set on CE Mark approval in the European Union in the 2nd quarter and the launch of a pivotal trial of the C-Pulse device in the 3rd quarter this year.

Although the cardiac rhythm management market has been a tough one in recent years, Rosa remains ever optimistic, especially after an FDA advisory panel recommended approval for HeartWare International‘s (NSDQ:HTWR) HVAD implantable heart pump for people with end-stage heart failure.

"Any person that’s CEO for an early-stage company will probably tell you something similar. The major challenges are really capital and being able to get capital to really achieve all the objectives that you have," he said. "What’s really encouraging, and why I’m so encouraged, is that I believe the recent approval of HeartWare’s device, or the recommendation by the panel to approve the device, is so important in that it gives investors additional confidence that the FDA is willing to approve and looking to approve devices in this space."

In an exclusive podcast interview with MassDevice.com, Rosa told us about the company’s beginnings, his optimism for the still-sluggish cardiac rhythm management market and the road ahead for Sunshine Heart.

Click here to listen to the podcast

Filed Under: News Well Tagged With: Cardiac Rhythm Management, MassDevice Q&A, Sunshine Heart Inc.

In case you missed it

  • Leading Medical UX Trends
  • Ex-Acclarent execs fined $1.5M in off-label marketing case
  • CDER head Woodcock to lead FDA for now
  • Prosecutors want to present evidence of Elizabeth Holmes’ quest for wealth and fame
  • TransEnterix raises more than $31M in stock offering
  • Boston Scientific launches WaveWriter Alpha spinal cord stim
  • What’s next for the FDA and for Stephen Hahn?
  • Apple magnetic charger, smartwatch may deactivate Medtronic ICD
  • Medicare to cover breakthrough devices
  • FDA debuts plan for AI-based Software as a Medical Device
  • EU allows remote audits for medical devices during pandemic
  • Smith+Nephew sees Movemedical automating inventory for its sales people
  • BD stock up on Street-beating preliminary quarterly revenue numbers
  • Boston Scientific’s preliminary Q4 results show 6.8% revenue decline
  • BREAKING: Steris to acquire Cantel Medical in $4.6B deal
  • FDA grants EUA for RapCov rapid COVID-19 antibody test
  • Former Corindus CEO Toland joins robotic `micro’ surgical startup

RSS From Medical Design & Outsourcing

  • Reflow Medical launches low-profile reinforced support catheters
    Reflow Medical today announced it has launched its Reflow Spex Low Profile reinforced support catheters. The Spex LP catheters are designed to provide the lowest profile tip to access and cross the tightest and most complex lesions with a supportive system. It comes in 0.014 in. and 0.018 in. sizes and can be combined with… […]
  • CDER head Woodcock to lead FDA for now
    FDA veteran Dr. Janet Woodcock has been tapped as interim FDA commissioner by the Biden administration, according to published reports. An article by BioCentury also said that former FDA commissioner David Kessler, who had been mentioned as a possible replacement for current commissioner Stephen Hahn, will be a consultant to the agency but will not… […]
  • What’s next for the FDA and for Stephen Hahn?
    Outgoing FDA commissioner Stephen Hahn says he needs some time to reflect on his future after leading the FDA for a little over a year. It’s hard to blame him. Hahn’s brief tenure at FDA has been rocky, to say the least. (News of his temporary replacement broke on Thursday, when the incoming Biden administration… […]
  • Medicare to cover breakthrough devices
    FDA-designated breakthrough devices will have Medicare coverage the same day they are approved, under a final rule issued this week by the Centers for Medicare and Medicaid Services (CMS). The Medicare Coverage of Innovative Technology (MCIT) rule will provide national Medicare coverage as early as the same day as FDA market authorization for breakthrough devices… […]
  • FDA debuts plan for AI-based Software as a Medical Device
    The FDA today released its first plan to regulate artificial intelligence/machine learning (AI/ML)-based Software as a Medical Device (SaMD). The plan is a response to feedback received from the agency’s April 2019 discussion paper, “Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning-Based Software as a Medical Device.” It outlines five actions that the FDA… […]
  • EU allows remote audits for medical devices during pandemic
    The European Union has announced that it will temporarily allow remote audits of medical devices and in vitro diagnostics under the new regulations (MDR IVDR), set to go into effect on May 2021 and 2022 respectively. In a document published Monday, the European Commission agreed with industry and notified bodies that the ongoing COVID-19 pandemic… […]
  • Apple magnetic charger, smartwatch may deactivate Medtronic ICD
    A new study in the Heart Rhythm Journal showed a magnetic charger for the iPhone 12 was able to deactivate a Medtronic implantable cardioverter defibrillator (ICD). The iPhone 12 has a circular array of magnets deployed around a central charging coil, making it compatible with the company’s wireless “MagSafe” accessories, according to the study published… […]
  • BREAKING: Steris to acquire Cantel Medical in $4.6B deal
    Steris (NYSE:STE) announced today that it will acquire Cantel Medical (NYSE:CMD) for $4.6 billion — a major merger in the infection prevention space. The deal is expected to close by June 30, pending customary closing conditions, regulatory approvals and an OK by Cantel shareholders. News of the merger comes a month and a half after Steris closed… […]
  • How Abbott stayed two steps ahead of COVID-19
    Developing a fast COVID-19 that resembled a pregnancy test and building two factories to boost productions — those were but two of the quick-thinking actions that Abbott (NYSE:ABT) officials took in the early months of a deadly coronavirus pandemic. Abbott began tracking the virus in China at the end of 2019 and into early 2020. By February,… […]
  • BREAKING: Big medtech suspends political contributions in wake of Electoral College vote
    Just as they lined up to condemn last week’s attack on the U.S. Capitol, major medtech companies are suspending political contributions because of 147 federal lawmakers’ refusal to acknowledge the Electoral College win by President-elect Joe Biden and Vice President-elect Kamala Harris. Boston Scientific announced on Sunday that it has chosen to temporarily suspend its… […]
  • Neurofeedback could help prostheses feel lighter: Here’s how
    Researchers at ETH Zurich have developed a prosthesis system that connects to the body’s nervous system to help amputees perceive a prosthetic weight as lower. The prosthesis system provides feedback to the wearer using electrodes implanted in the thigh that are connected to the leg nerves. Information from the tactile sensors under the sole of… […]

Leave a Reply Cancel reply

You must be logged in to post a comment.

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS